Joab Camarena

3.9k total citations · 3 hit papers
16 papers, 2.3k citations indexed

About

Joab Camarena is a scholar working on Molecular Biology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Joab Camarena has authored 16 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Genetics and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Joab Camarena's work include CRISPR and Genetic Engineering (15 papers), Hemoglobinopathies and Related Disorders (6 papers) and Mosquito-borne diseases and control (4 papers). Joab Camarena is often cited by papers focused on CRISPR and Genetic Engineering (15 papers), Hemoglobinopathies and Related Disorders (6 papers) and Mosquito-borne diseases and control (4 papers). Joab Camarena collaborates with scholars based in United States, India and Spain. Joab Camarena's co-authors include Matthew H. Porteus, Daniel P. Dever, Mara Pavel-Dinu, Rasmus O. Bak, Sruthi Mantri, Kenneth I. Weinberg, Natalia Gomez‐Ospina, Mark A. Behlke, Christopher A. Vakulskas and Michael A. Collingwood and has published in prestigious journals such as Nature, Nucleic Acids Research and Nature Medicine.

In The Last Decade

Joab Camarena

15 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of preexisting adaptive immunity to Cas9 proteins in humans

2019 665 citations Carsten T. Charlesworth, Daniel P. Dever et al. Nature Medicine profile →
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

2016 641 citations Daniel P. Dever, Rasmus O. Bak et al. Nature profile →
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells

2018 541 citations Christopher A. Vakulskas, Daniel P. Dever et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joab Camarena United States	11	2.1k	807	328	267	231	16	2.3k
Mara Pavel-Dinu United States	9	1.9k 0.9×	766 0.9×	362 1.1×	166 0.6×	214 0.9×	16	2.1k
Ayal Hendel Israel	22	2.6k 1.3×	782 1.0×	405 1.2×	187 0.7×	221 1.0×	37	2.8k
Sruthi Mantri United States	6	1.4k 0.7×	593 0.7×	262 0.8×	167 0.6×	153 0.7×	9	1.6k
Alec B. Wilkens United States	3	1.3k 0.6×	446 0.6×	218 0.7×	142 0.5×	146 0.6×	4	1.5k
Pietro Genovese United States	16	2.4k 1.2×	1.4k 1.8×	853 2.6×	175 0.7×	158 0.7×	35	3.0k
S. Kaye Spratt United States	18	1.6k 0.8×	623 0.8×	270 0.8×	100 0.4×	116 0.5×	24	2.2k
Roger P. Hollis United States	27	1.7k 0.8×	1.1k 1.4×	425 1.3×	261 1.0×	55 0.2×	58	2.2k
Xavier M. Anguela United States	17	1.7k 0.8×	1.3k 1.6×	476 1.5×	101 0.4×	62 0.3×	31	2.2k
Siyuan Tan United States	10	1.7k 0.8×	510 0.6×	116 0.4×	95 0.4×	115 0.5×	22	2.0k
Richard L. Frock United States	18	2.1k 1.0×	313 0.4×	249 0.8×	54 0.2×	131 0.6×	29	2.3k

Countries citing papers authored by Joab Camarena

Since Specialization

Citations

This map shows the geographic impact of Joab Camarena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joab Camarena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joab Camarena more than expected).

Fields of papers citing papers by Joab Camarena

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joab Camarena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joab Camarena. The network helps show where Joab Camarena may publish in the future.

Co-authorship network of co-authors of Joab Camarena

This figure shows the co-authorship network connecting the top 25 collaborators of Joab Camarena. A scholar is included among the top collaborators of Joab Camarena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joab Camarena. Joab Camarena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Camarena, Joab, Jessica P. Hampton, Carsten T. Charlesworth, et al.. (2024). Enhancement of erythropoietic output by Cas9-mediated insertion of a natural variant in haematopoietic stem and progenitor cells. Nature Biomedical Engineering. 8(12). 1540–1552. 2 indexed citations

Camarena, Joab, et al.. (2023). Demographic and socioeconomic disparities in receipt of ophthalmology consultation for facial trauma. BMJ Open Ophthalmology. 8(1). e001259–e001259.

Wilkinson, Adam C., Daniel P. Dever, Ron Baik, et al.. (2021). Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nature Communications. 12(1). 686–686. 69 indexed citations

Sharma, Rajiv P., Daniel P. Dever, Ciaran M. Lee, et al.. (2021). The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. Nature Communications. 12(1). 472–472. 21 indexed citations

Quintana-Bustamante, Óscar, Daniel P. Dever, Rebeca Sánchez‐Domínguez, et al.. (2021). Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency. Molecular Therapy — Methods & Clinical Development. 22. 237–248. 13 indexed citations

Srifa, Waracharee, Nina Kosaric, Sruthi Mantri, et al.. (2020). Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice. Nature Communications. 11(1). 2470–2470. 61 indexed citations

Charlesworth, Carsten T., Daniel P. Dever, Joab Camarena, et al.. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine. 25(2). 249–254. 665 indexed citations breakdown →

Dever, Daniel P., Joab Camarena, Eric Kildebeck, et al.. (2019). CRISPR/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells. iScience. 15. 524–535. 34 indexed citations

Park, So Hyun, Ciaran M. Lee, Daniel P. Dever, et al.. (2019). Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Research. 47(15). 7955–7972. 110 indexed citations

10.

Vakulskas, Christopher A., Daniel P. Dever, Garrett R. Rettig, et al.. (2018). A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nature Medicine. 24(8). 1216–1224. 541 indexed citations breakdown →

11.

Cromer, M. Kyle, Sriram Vaidyanathan, Daniel E. Ryan, et al.. (2018). Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells. Molecular Therapy. 26(10). 2431–2442. 87 indexed citations

12.

Charlesworth, Carsten T., Joab Camarena, M. Kyle Cromer, et al.. (2018). Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. Molecular Therapy — Nucleic Acids. 12. 89–104. 76 indexed citations

13.

Quintana-Bustamante, Óscar, Daniel P. Dever, Joab Camarena, et al.. (2018). Efficient CRISPR/Cas9-Mediated Gene Editing of Pklr in Human Hematopoietic Progenitors and Stem Cells for the Gene Therapy of Pyruvate Kinase Deficiency. Blood. 132(Supplement 1). 5792–5792. 1 indexed citations

14.

Park, So Hyun, Ciaran M. Lee, Daniel P. Dever, et al.. (2018). Highly Efficient Editing of the Beta-Globin Gene in Patient Derived Hematopoietic Stem and Progenitor Cells to Treat Sickle Cell Disease. Blood. 132(Supplement 1). 2192–2192. 4 indexed citations

15.

Dever, Daniel P., Joab Camarena, Ciaran M. Lee, et al.. (2017). Preclinical Development of HBB Gene Correction in Autologous Hematopoietic Stem and Progenitor Cells to Treat Severe Sickle Cell Disease. Blood. 130. 4620–4620. 4 indexed citations

16.

Dever, Daniel P., Rasmus O. Bak, Andreas Reinisch, et al.. (2016). CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 539(7629). 384–389. 641 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact